Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706892 | 1.00 | SLC2A1 (0.35) | SLC2A1CYP11B2JAK2JAK3GRIN2B | |
| SCHEMBL19706841 | 0.95 | KCNH2 (0.35) | SLC2A1CYP11B2JAK2JAK3GRIN2B | |
| SCHEMBL19708645 | 0.95 | KCNH2 (0.35) | SLC2A1CYP11B2JAK2JAK3GRIN2B | |
| SCHEMBL20996021 | 0.93 | KCNH2 (0.39) | SLC2A1KCNH2 | |
| SCHEMBL20996020 | 0.93 | KCNH2 (0.39) | SLC2A1KCNH2 | |
| SCHEMBL20995986 | 0.91 | CCR3 (0.32) | JAK2JAK3GRIN2BKCNH2 | |
| SCHEMBL19707017 | 0.91 | CCR3 (0.32) | JAK2JAK3GRIN2BKCNH2 | |
| SCHEMBL19707016 | 0.91 | CCR3 (0.32) | JAK2JAK3GRIN2BKCNH2 | |
| SCHEMBL19707063 | 0.90 | KCNH2 (0.39) | SLC2A1KCNH2 | |
| SCHEMBL20995997 | 0.90 | KCNH2 (0.39) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| EP-3468975-B1 | NEW ANTIBACTERIAL COMPOUNDS | ACRAF (IT) | 2020-04-01 | — | — | EP | disclosed |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-22 | — | — | US | disclosed |
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, LAS1L, MRPL19 | SLC2A1 4456/4885CYP11B2 4112/4885JAK2 3126/4885 |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | SLC2A1 4408/4885CYP11B2 4546/4885JAK2 4407/4885 |
| US-10633366-B2 | Antibacterial compounds | MRPL21, LAS1L, MRPL19 | SLC2A1 4448/4885CYP11B2 3856/4885JAK2 2504/4885 |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | SLC2A1 4408/4885CYP11B2 4546/4885JAK2 4407/4885 |
| US-10640488-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | SLC2A1 4378/4885CYP11B2 4539/4885JAK2 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.